Select Publications
Book Chapters
, 2016, '- Metabolomics: An Important Tool for Assessing State of Health and Risk of Disease in Nutrigenomics Research', in Nutrigenomics and Nutrigenetics in Functional Foods and Personalized Nutrition, CRC Press, pp. 248 - 261, http://dx.doi.org/10.1201/b15369-15
2016, 'Metabolomics: An important tool for assessing state of health and risk of disease in nutrigenomics research', in Nutrigenomics and Nutrigenetics in Functional Foods and Personalized Nutrition, pp. 229 - 242
,Journal articles
2024, 'Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance', Journal of Clinical Investigation, 134, http://dx.doi.org/10.1172/JCI183583
,2024, 'Circulating Lipid Profiles Associated with Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.24.00260
,2024, 'Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer', Prostate, 84, pp. 747 - 755, http://dx.doi.org/10.1002/pros.24691
,2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690
,2024, 'Abstract 5480: Single cell and spatial transcriptomic profile of appendiceal tumour peritoneal disease', Cancer Research, 84, pp. 5480 - 5480, http://dx.doi.org/10.1158/1538-7445.am2024-5480
,2024, 'PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, 27, pp. 136 - 143, http://dx.doi.org/10.1038/s41391-023-00666-2
,2024, '1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', Annals of Oncology, 35, pp. S969 - S970, http://dx.doi.org/10.1016/j.annonc.2024.08.1688
,2023, 'Circulating ether lipids in prostate cancer.', Journal of Clinical Oncology, 41, pp. e17009 - e17009, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17009
,2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031
,2023, 'Characteristics of immune-infiltrating cells in the tumor microenvironment of appendiceal cancer with peritoneal disease.', Journal of Clinical Oncology, 41, pp. 217 - 217, http://dx.doi.org/10.1200/jco.2023.41.4_suppl.217
,2023, 'Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer', JCO Clinical Cancer Informatics, 7, http://dx.doi.org/10.1200/CCI.23.00057
,2023, '1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?', Annals of Oncology, 34, pp. S991 - S991, http://dx.doi.org/10.1016/j.annonc.2023.09.2779
,2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0
,2022, 'Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14194792
,2022, 'Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants', Cancers, 14, http://dx.doi.org/10.3390/cancers14071708
,2022, '1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention', Annals of Oncology, 33, pp. S1189 - S1189, http://dx.doi.org/10.1016/j.annonc.2022.07.1895
,2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625
,2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964
,2021, 'Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, 24, pp. 860 - 870, http://dx.doi.org/10.1038/s41391-021-00338-z
,2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration resistant prostate cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p032
,2019, 'Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial', European Urology, 76, pp. 306 - 312, http://dx.doi.org/10.1016/j.eururo.2018.11.001
,2019, 'Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer', Molecular Cancer Research, 17, pp. 949 - 962, http://dx.doi.org/10.1158/1541-7786.MCR-18-0347
,2018, 'MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-26050-y
,2018, 'Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer', Prostate, 78, pp. 308 - 317, http://dx.doi.org/10.1002/pros.23476
,2018, 'MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer', , http://dx.doi.org/10.1101/273284
,2017, 'A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer', International Journal of Cancer, 141, pp. 2112 - 2120, http://dx.doi.org/10.1002/ijc.30903
,2017, 'Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 35, pp. 5014 - 5014, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5014
,2017, 'Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer', British Journal of Cancer, 116, pp. 1002 - 1011, http://dx.doi.org/10.1038/bjc.2017.50
,2016, 'Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer', Prostate, 76, pp. 1491 - 1500, http://dx.doi.org/10.1002/pros.23233
,2016, 'Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 34, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.5039
,2015, 'Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer', British Journal of Cancer, 112, pp. 1340 - 1348, http://dx.doi.org/10.1038/bjc.2015.74
,2014, 'Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer', British Journal of Cancer, 110, pp. 2462 - 2471, http://dx.doi.org/10.1038/bjc.2014.181
,2013, 'Focal adhesion kinase: a mediator of docetaxel-resistance in castrate resistant prostate cancer', BJU INTERNATIONAL, 112, pp. 38 - 39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 31, pp. e22175 - e22175, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22175
,2013, 'Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer', Molecular Cancer Therapeutics, 13, pp. 190 - 201, http://dx.doi.org/10.1158/1535-7163.MCT-13-0225-T
,2011, 'Metabolomic analysis reveals differences in urinary excretion of kiwifruit-derived metabolites in a mouse model of inflammatory bowel disease', Molecular Nutrition and Food Research, 55, pp. 1900 - 1904, http://dx.doi.org/10.1002/mnfr.201100302
,2011, 'Using metabolomic analysis to understand inflammatory bowel diseases', Inflammatory Bowel Diseases, 17, pp. 1021 - 1029, http://dx.doi.org/10.1002/ibd.21426
,2011, 'Identification of urinary biomarkers of colon inflammation in IL10 -/- mice using short-column LCMS metabolomics', Journal of Biomedicine and Biotechnology, 2011, http://dx.doi.org/10.1155/2011/974701
,2010, 'Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn?s disease', Journal of Proteome Research, 9, pp. 1965 - 1975, http://dx.doi.org/10.1021/pr901130s
,2009, 'Nontargeted urinary metabolite profiling of a mouse model of crohn's disease', Journal of Proteome Research, 8, pp. 2045 - 2057, http://dx.doi.org/10.1021/pr800999t
,2007, 'Genome wide expression profiling identifies genes associated with colorectal liver metastasis', Oncology Reports, 17, pp. 1541 - 1549, http://dx.doi.org/10.3892/or.17.6.1541
,2005, 'Crosslinking of wheat dough proteins by glucose oxidase and the resulting effects on bread and croissants', Food Chemistry, 89, pp. 325 - 332, http://dx.doi.org/10.1016/j.foodchem.2004.02.052
,2005, 'Stability of the insecticide cypermethrin during tomato processing and implications for endocrine activity', Food Additives and Contaminants, 22, pp. 15 - 22, http://dx.doi.org/10.1080/02652030400027938
,2004, 'Ranking the risk of pesticide dietary intake', Pest Management Science, 60, pp. 842 - 848, http://dx.doi.org/10.1002/ps.904
,Conference Papers
2017, 'The plasma lipidome in castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5055
,2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605294&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, pp. 48 - 49, presented at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, 06 November 2012 - 09 November 2012, http://dx.doi.org/10.1016/S0959-8049(12)71956-1
,Conference Abstracts
2022, 'Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1322 - S1322, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1791
,